Forecast

The analysts' average price target is €6.88 (+175.20%). The median is €6.88 (+175.20%).

Buy	1
Hold	0
Sell	0

News Go to news feed

SeaStar Medical: shareholders approve expansion of stock plan and board election

SeaStar Medical shareholders elected John Neuman to the board of directors and approved a revised omnibus incentive plan that increases authorized common shares from 207,046 to 896,546. They also confirmed WithumSmith+Brown as the independent auditor for the fiscal year ending December 31, 2026, and granted the board the right to adjourn the annual meeting if necessary. The stock last traded at $3.06 after a weekly gain of more than 16%, but is down roughly 68% year-to-date. SeaStar reported strong revenue growth in the first quarter of 2026, attributed to the product QUELIMMUNE, and has a current ratio of 2.73. » More on de.investing.com
SeaStar Medical reports 69% revenue increase in Q1 2026 thanks to QUELIMMUNE

SeaStar Medical recorded a 69% revenue rise in the first quarter of 2026 to US$495,000, driven by increased use of the QUELIMMUNE therapy for pediatric acute kidney injury. Gross margin remained above 90% with stable operating expenses of US$4.1 million; net loss narrowed slightly to US$3.5 million. The customer base grew to 17 hospitals, and the company is targeting about US$2 million in revenue for 2026 and an expansion of adult clinical trials. Investors reacted cautiously; the stock fell 3.57% in premarket trading. » More on de.investing.com
SeaStar Medical reports Q1 2026: revenue rises 69% thanks to QUELIMMUNE, liquidity significantly improved

SeaStar Medical posted 69% revenue growth in Q1 2026 to $495,000, driven by rising adoption of the QUELIMMUNE therapy and expansion to 17 hospitals. Gross margin remained high at over 90%, net loss narrowed to $3.5 million, and earnings per share improved to -$0.90. Cash and equivalents increased 79% to $9.3 million following a capital raise; the stock rose slightly in after-hours trading. For 2026 the company targets roughly $2 million in net revenue and plans a moderate increase in R&D spending to support ongoing studies. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, SeaStar Medical has already paid €0.36 in dividends. The last payout was in March 2022.

Financials

In the last quarter, SeaStar Medical had revenue of €538.87K and net profit of -€3.27M

(EUR)	June 2026	YoY
Revenue	538.87K	87.91%
Gross profit	491.55K	86.29%
Net profit	-3.27M	92.42%
EBITDA	-3.25M	92.15%

Fundamentals

Metric	Value
Market capitalization	€7.04M
Number of shares	2.84M
52-week high/low	€10.75 - €1.78
Dividends	No
Beta	-1.04
P/E ratio	-0.74
PEG ratio	0.00
P/B ratio	2.74
P/S ratio	4.78

Company profile

SeaStar Medical Holding Corporation, ein Medizintechnikunternehmen, konzentriert sich auf die Bereitstellung neuartiger Lösungen und Dienstleistungen zur Behandlung von Hyperinflammation und Zytokinsturm bei schwerkranken Patienten. Das Unternehmen entwickelt und vermarktet extrakorporale Therapien, die auf die Effektorzellen abzielen, die die systemische Entzündung vorantreiben, direkte Gewebeschäden verursachen und eine Reihe von entzündungsfördernden Zytokinen absondern, die unausgewogene Immunreaktionen auslösen und verstärken. Das Unternehmen entwickelt Produkte in verschiedenen therapeutischen Bereichen, darunter akute Nierenschäden bei Kindern und Erwachsenen unter CRRT, kardiorenales Syndrom bei kongestiver Herzinsuffizienz mit und ohne LVAD, Myokardbetäubung bei Nierenerkrankungen im Endstadium und hepatorenales Syndrom. Das Unternehmen hat seinen Sitz in Denver, Colorado.